User profiles for Samuel C. Blackman
 | Samuel C. BlackmanSenior Vice President, Silverback Therapeutics Verified email at silverbacktx.com Cited by 2384 |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
…, M Millward, AC Pavlick, SJ O'Day, SC Blackman… - The Lancet, 2012 - thelancet.com
Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We
aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in …
aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in …
[HTML][HTML] The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
…, A Walter, D Da Costa, P Manley, SC Blackman… - Nature medicine, 2024 - nature.com
BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade
glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …
glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …
[HTML][HTML] BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for …
Activating oncogenic mutations of BRAF have been described in patients with gastrointestinal
stromal tumor (GIST), but treatment of GIST with BRAF inhibitors and mechanisms of …
stromal tumor (GIST), but treatment of GIST with BRAF inhibitors and mechanisms of …
Postcesarean analgesia with both epidural morphine and intravenous patient-controlled analgesia: neurobehavioral outcomes among nursing neonates
…, JA Senal, SM Cox, SC Blackman… - Anesthesia & …, 1997 - journals.lww.com
Among nursing parturients after cesarean delivery, intravenous patient-controlled analgesia
(PCA) with meperidine is associated with significantly more neonatal neurobehavioral …
(PCA) with meperidine is associated with significantly more neonatal neurobehavioral …
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)
…, A Pavlick, MT Chin, SJ O'Day, SC Blackman… - Clinical Cancer …, 2014 - AACR
Purpose: Dabrafenib is a selective, potent ATP-competitive inhibitor of the BRAFV600-mutant
kinase that has demonstrated efficacy in clinical trials. We report the rationale for dose …
kinase that has demonstrated efficacy in clinical trials. We report the rationale for dose …
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation‐positive tumors
…, G Pande, EC Krachey, SC Blackman… - Journal of …, 2013 - Wiley Online Library
Dabrafenib is a small‐molecule inhibitor of BRAF kinase activity that is currently being
developed for the treatment of BRAF V600 mutation‐positive melanoma. This clinical, open‐label, …
developed for the treatment of BRAF V600 mutation‐positive melanoma. This clinical, open‐label, …
Assessment of the drug interaction potential and single‐and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib
…, MR Middleton, SC Blackman… - The Journal of …, 2015 - Wiley Online Library
The induction of CYP2C9 by dabrafenib using S‐warfarin as a probe and the effects of a
CYP3A inhibitor (ketoconazole) and a CYP2C8 inhibitor (gemfibrozil) on dabrafenib …
CYP3A inhibitor (ketoconazole) and a CYP2C8 inhibitor (gemfibrozil) on dabrafenib …
Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following …
…, N Nebot, SW Carson, SC Blackman… - Drug Metabolism and …, 2013 - ASPET
A phase I study was conducted to assess the metabolism and excretion of [ 14 C]dabrafenib
(GSK2118436; N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-…
(GSK2118436; N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-…
Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation‐positive solid tumors
…, C Han, RA Morrison, SC Blackman… - The Journal of …, 2013 - Wiley Online Library
… Chao Han and Samuel C. Blackman were former paid employees and stockholders of
GlaxoSmithKline at the time of this study and analysis. Funding for this study (NCT01340833) was …
GlaxoSmithKline at the time of this study and analysis. Funding for this study (NCT01340833) was …
[HTML][HTML] LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade …
…, A Koch, F Sahm, J Qiu, LP Tsao, SC Blackman… - BMC cancer, 2024 - Springer
Background Pediatric low-grade glioma (pLGG) is essentially a single pathway disease, with
most tumors driven by genomic alterations affecting the mitogen-activated protein kinase/…
most tumors driven by genomic alterations affecting the mitogen-activated protein kinase/…